Publications
Position Papers
Two foundational documents establishing the philosophical premise and the contemporary institutional case for clinical research designed for neurodivergent adults.
Position Paper · April 2026
The Misidentified Variable
Our position paper argues that neurodivergence itself has been misidentified in clinical research — treated as pathology rather than as a distinct cognitive phenotype. We propose a new framework: neurodivergence-by-postulation, a methodology that centers neurodivergent experience, measures outcomes that matter to neurodivergent people, and designs interventions from first principles rather than neurotypical adaptation.
What's Inside
The Misidentification Argument
Why decades of neurodivergence research have measured the wrong variable — and how that error compounds across methodology, intervention design, and outcome measurement.
Neurodivergence-by-Postulation
A proposed research framework that treats neurodivergent cognition as a starting premise rather than a deviation to be corrected.
Implications for Psychedelic Research
How the misidentified variable has shaped — and distorted — existing psychedelic therapy trials for autistic and neurodivergent populations.
Position Paper · May 2026
The Recognition Asymmetry
A growing body of corporate, academic, and capital-markets evidence demonstrates that neurodivergent cognitive styles produce measurable competitive advantage in technology, finance, and artificial intelligence. The clinical research infrastructure serving the same population has not yet adapted. This paper documents the asymmetry and articulates the institutional case for sustained investment in clinical research designed for neurodivergent adults.
What's Inside
The Asymmetry Documented
Corporate hiring data, capital-markets research, and academic literature demonstrating that neurodivergent cognitive profiles produce measurable competitive advantage — while clinical research infrastructure has not kept pace.
The Infrastructure Gap
An analysis of why the clinical research apparatus serving neurodivergent adults remains underfunded, under-designed, and misaligned with the population it purports to serve.
The Institutional Case
A direct argument for sustained philanthropic and institutional investment in neurodivergent-centered clinical research — grounded in economic, ethical, and scientific rationale.
Pharmacological Thesis · 2026
2C-B and Neurodivergence: A Pharmacological Thesis
This paper synthesizes peer-reviewed pharmacological literature, controlled human research, and clinical theory to establish the rationale for 2C-B-assisted therapy in autistic and neurodivergent populations. It introduces the Karame Protocol — a four-domain integrative framework with three-tier dosing architecture — and outlines a phased research agenda from instrument validation through controlled efficacy trials.
Listen to Audio Version
What's Inside
Pharmacological Rationale
Mixed 5-HT2A/5-HT2C/SERT mechanism, dose-dependent entactogenic-to-psychedelic spectrum, preserved cognitive clarity, shorter duration — and why this profile is uniquely relevant for sensory processing, alexithymia, and emotional dysregulation in autism.
The Karame Protocol
A four-domain integrative framework (Intellect, Emotion, Spirit, Body) with three-tier dosing architecture (microdose maintenance, entactogenic session, psychedelic session) designed specifically for neurodivergent trauma resolution.
Existing Evidence Base
Comprehensive review of controlled 2C-B research (Maastricht, Basel), broader psychedelic-autism literature (psilocybin, MDMA, ketamine), and community evidence — establishing both the gap and the opportunity.
Phased Research Agenda
Phase 0 (instrument validation), Phase 1 (pilot characterization with 7T fMRI), Phase 2 (open-label protocol pilot), Phase 3 (controlled efficacy trial) — with cost estimates, timeline, and go/no-go decision points.
Ethical Framework
Neurodivergent-centered research design, community advisory panels, trauma-informed consent, and the moral imperative to investigate compounds that may reduce suffering — not to optimize productivity.
This paper has not been peer-reviewed or published in an academic journal. It is a working document that synthesizes existing peer-reviewed literature to establish the research agenda of The Cedar Institute.